• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about TC Biopharm

Recent news which mentions TC Biopharm

3 Patients Already Dosed In TC BioPharm's Phase 2b Trial Of A Cutting Edge T Cell Therapy For Hard-to-Treat Cancers
January 26, 2023
Tickers TCBP
Tags Penny Stocks Partner Content TCBP
From Benzinga
TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemia
November 22, 2022
Tickers TCBP TCBPW
Tags TCBPW TC Biopharm News
From Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
Tickers ACET BMY IPSC TAK
Tags General Biotech ACET
From Benzinga
TC BioPharm Says It Aims To Deliver A Big Breakthrough In Cancer Treatments
August 08, 2022
Tickers BMY TCBP TECH
Tags Penny Stocks Partner Content Biotech
From Benzinga
TC BioPharm Reports Racing Toward What Could Be A Major Cancer Immunotherapy Breakthrough
June 02, 2022
Tickers BLUE TCBP
Tags BLUE TC Biopharm Penny Stocks
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap